Novel therapeutic strategies for patients with triple-negative breast cancer

Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast diseases. Currently, the backbone of therapy for TNBC is mainly chemotherapy as there are no effective specific targeted agents approved to treat TNBC. Despite initial responses to chemotherapy, resistance frequentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jun-Fei, Liu, Jia, Wang, Yu, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085278/
https://www.ncbi.nlm.nih.gov/pubmed/27799799
http://dx.doi.org/10.2147/OTT.S105716
_version_ 1782463542112288768
author Zhang, Jun-Fei
Liu, Jia
Wang, Yu
Zhang, Bin
author_facet Zhang, Jun-Fei
Liu, Jia
Wang, Yu
Zhang, Bin
author_sort Zhang, Jun-Fei
collection PubMed
description Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast diseases. Currently, the backbone of therapy for TNBC is mainly chemotherapy as there are no effective specific targeted agents approved to treat TNBC. Despite initial responses to chemotherapy, resistance frequently and rapidly develops and metastatic TNBC has a poor prognosis. Therefore, new targeted strategies are, accordingly, urgently needed. This article discusses the recent developments in targeted agents explored for TNBC, aiming to offer novel therapeutic strategies that can potentially assist in designing personalized therapeutics in the future as well as provide the basis for further research in an attempt to target TNBC.
format Online
Article
Text
id pubmed-5085278
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50852782016-10-31 Novel therapeutic strategies for patients with triple-negative breast cancer Zhang, Jun-Fei Liu, Jia Wang, Yu Zhang, Bin Onco Targets Ther Review Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast diseases. Currently, the backbone of therapy for TNBC is mainly chemotherapy as there are no effective specific targeted agents approved to treat TNBC. Despite initial responses to chemotherapy, resistance frequently and rapidly develops and metastatic TNBC has a poor prognosis. Therefore, new targeted strategies are, accordingly, urgently needed. This article discusses the recent developments in targeted agents explored for TNBC, aiming to offer novel therapeutic strategies that can potentially assist in designing personalized therapeutics in the future as well as provide the basis for further research in an attempt to target TNBC. Dove Medical Press 2016-10-21 /pmc/articles/PMC5085278/ /pubmed/27799799 http://dx.doi.org/10.2147/OTT.S105716 Text en © 2016 Zhang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhang, Jun-Fei
Liu, Jia
Wang, Yu
Zhang, Bin
Novel therapeutic strategies for patients with triple-negative breast cancer
title Novel therapeutic strategies for patients with triple-negative breast cancer
title_full Novel therapeutic strategies for patients with triple-negative breast cancer
title_fullStr Novel therapeutic strategies for patients with triple-negative breast cancer
title_full_unstemmed Novel therapeutic strategies for patients with triple-negative breast cancer
title_short Novel therapeutic strategies for patients with triple-negative breast cancer
title_sort novel therapeutic strategies for patients with triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085278/
https://www.ncbi.nlm.nih.gov/pubmed/27799799
http://dx.doi.org/10.2147/OTT.S105716
work_keys_str_mv AT zhangjunfei noveltherapeuticstrategiesforpatientswithtriplenegativebreastcancer
AT liujia noveltherapeuticstrategiesforpatientswithtriplenegativebreastcancer
AT wangyu noveltherapeuticstrategiesforpatientswithtriplenegativebreastcancer
AT zhangbin noveltherapeuticstrategiesforpatientswithtriplenegativebreastcancer

Ejemplares similares